Pharmacoperones and the calcium sensing receptor: Exogenous and endogenous regulators
详细信息 查看全文
- 作者：Gerda E. Breitwieser ; gebreitwieser@geisinger.edu" class="auth_mail
- 关键词：ADH ; autosomal dominant hypocalcemia ; CaSR ; calcium sensing receptor ; xCT ; cystine-glutamate transporter ; DHPs ; dihydropyridines ; EAAT ; excitatory amino acid transporter ; EGFR ; endothelial growth factor receptor ; ER ; endoplasmic reticulum ; ERK1/2 ; extracellular signal activated kinase 1 and 2 ; ER QC ; endoplasmic reticulum quality control ; FHH ; familial hypocalciuric hypercalcemia ; FIH ; familial isolated hypoparathyroidism ; GABA ; gamma amino isobutyric acid ; GCM2 ; glial cells missing homolog 2 ; G
- 刊名：Pharmacological Research
- 出版年：May 2014
- 年：2014
- 卷：83
- 期：Complete
- 页码：30-37
- 全文大小：1081 K
文摘
Calcium sensing receptor (CaSR) mutations or altered expression cause disorders of calcium handling. Recent studies suggest that reduced targeting to the plasma membrane is a feature common to many CaSR loss-of-function mutations. Allosteric agonists (calcimimetics) can rescue signaling of a subset of CaSR mutants. This review evaluates our current understanding of the subcellular site(s) for allosteric modulator rescue of CaSR mutants. Studies to date make a strong case for calcimimetic potentiation of signaling not only at plasma membrane-localized CaSR, but at the endoplasmic reticulum, acting as pharmacoperones to assist in navigation of multiple quality control checkpoints. The possible role of endogenous pharmacoperones, calcium and glutathione, in folding and stabilization of the CaSR extracellular and transmembrane domains are considered. Finally, the possibility that dihydropyridines act as unintended pharmacoperones of CaSR is proposed. While our understanding of pharmacoperone rescue of CaSR requires refinement, promising results to date argue that this may be a fruitful avenue for drug discovery.